Compare Endeavour Silver Corp (EXK) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Organon & Co. Common Stock — how do they compare? Endeavour Silver Corp trades at $8 (market cap $2.32B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 26 Days and Organon & Co. Common Stock for 0 Days on average.
| EXK | OGN | |
|---|---|---|
Market Cap | $2.32B | $3.61B |
Volume | 8,976,489 | 1,808,049 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $13.81 |
52-Week Low | $7.07 | $5.70 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $2.32B | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.24, down 3.51% today amid bearish technical signals. The company shows improving fundamentals with Q1 2026 earnings beating expectations and strong revenue growth projected for 2026. Recent news highlights operational progress at Terronera and Kolpa mines, though mechanical issues at Guanacevi and past blockades present challenges. Analyst sentiment remains predominantly bullish with 78.57% buy ratings.
EXK presents a growth story with expanding production capacity but faces execution risks. The stock's valuation appears elevated with a P/E of 39.15, requiring continued operational success to justify. Near-term catalysts include Terronera mine ramp-up and silver price movements, while operational disruptions and commodity volatility remain key risks for investors.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
